Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Switch patients from Atripla to Stribild will be evaluated to see if patients have less sleep disturbances.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Midtown Medical Center, Tampa, FL
• Collaborator: Gilead Sciences
• Treatments: Cobicistat; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Tenofovir

Criteria

Inclusion Criteria:

• HIV+ subjects 18 years of age or older

• estimated Glomerular Filtration Rate > 70 mL/min

• must currently be on Atripla and taking it for at least 3 months with a HIV-1 Viral Load < 50 copies/mL

• no antiretrovirals prior to the initiation of Atripla

• baseline genotyping

Exclusion Criteria:

• pregnancy

• unable to provide informed consent

• enrolled in another study